Chu Jinshen, Hua Lin, Liu Xiaofeng, Xiong Huomei, Jiang Fangtinghui, Zhou Wei, Wang Lu, Xue Guohui
Department of Clinical Laboratory, Jiujiang No.1 People's Hospital, Jiujiang, China.
Department of Microbiology, Jiujiang Center for Disease Control and Prevention, Jiujiang, China.
Front Immunol. 2024 Feb 22;15:1362102. doi: 10.3389/fimmu.2024.1362102. eCollection 2024.
In the few reports to date, the changes in superoxide dismutase (SOD), a key factor in cellular protection against superoxide, in COVID-19 have been very inconsistent and contradictory. There is also a lack of data on COVID-19 induced by Omicron variant. Further investigation is warranted to figure out SOD alterations in COVID-19, particularly within the context of ongoing Omicron variant infection, which may provide clues to its role within COVID-19 pathogenesis and open up new avenues for COVID-19 treatment.
SOD activity in 109 COVID-19 patients (including 46 severe cases and 63 mild to moderate cases) and 30 matched healthy controls were quantified. Demographic data, blood cell counts, biochemical indicators, coagulation indicators, and inflammatory markers were also recorded.
SOD, an important key node, experienced a significant decrease in COVID-19, with the severe patients exhibiting lower activity compared to the mild to moderate patients and control healthy. Notably, severe patients who deceased had the lowest SOD activity. Correlation analysis revealed significant correlations between SOD and inflammatory markers, organ injury markers, coagulation dysfunction indicators, nutritional markers, and lymphocytes counts. The ROC curve also showed good performance for the differentiation of severe cases and the prediction of death.
SOD activity was significantly decreased in COVID-19 infected with Omicron variant and significantly correlated with systemic changes, and could be used as a biomarker to assess disease severity and predict mortality in COVID-19 clinical pathway management. Additionally, this finding will contribute to exploring new potential direction for the treatment of severe COVID-19 patients.
在迄今为止为数不多的报告中,超氧化物歧化酶(SOD)这一细胞抵御超氧化物的关键因素在新冠病毒疾病(COVID-19)中的变化非常不一致且相互矛盾。关于奥密克戎变种引发的COVID-19的数据也很缺乏。有必要进一步研究以弄清楚COVID-19中SOD的变化,特别是在奥密克戎变种持续感染的背景下,这可能为其在COVID-19发病机制中的作用提供线索,并为COVID-19治疗开辟新途径。
对109例COVID-19患者(包括46例重症患者和63例轻至中度患者)以及30例匹配的健康对照者的SOD活性进行了定量分析。还记录了人口统计学数据、血细胞计数、生化指标、凝血指标和炎症标志物。
SOD作为一个重要的关键节点,在COVID-19中显著降低,重症患者的活性低于轻至中度患者和健康对照者。值得注意的是,死亡的重症患者SOD活性最低。相关性分析显示SOD与炎症标志物、器官损伤标志物、凝血功能障碍指标、营养标志物和淋巴细胞计数之间存在显著相关性。ROC曲线在区分重症病例和预测死亡方面也表现良好。
感染奥密克戎变种的COVID-19患者的SOD活性显著降低,且与全身变化显著相关,可作为评估COVID-19临床路径管理中疾病严重程度和预测死亡率的生物标志物。此外,这一发现将有助于探索治疗重症COVID-19患者的新潜在方向。